Genflow Biosciences PLC Announces Holding in Company

NYSE - LSE

CMSC	0.19%	21.03	$
BCC	0.62%	76.31	$
CMSD	0.05%	20.79	$
RIO	0.87%	102.75	$
GSK	-0.44%	50.44	$
BCE	-0.04%	23.4	$
BTI	-0.43%	55.68	$
BP	-1.23%	43.93	$
RBGPF	-3.2%	70	$
JRI	-0.75%	12.08	$
AZN	-0.52%	161.63	$
RELX	-1.56%	35.15	$
RYCEF	-0.15%	19.56	$
VOD	0.12%	16.07	$
NGG	-1.41%	78.05	$

Genflow Biosciences PLC Announces Holding in Company

BOULEVARD 28.03.2025

LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / 1. Issuer Details

Text size:

ISIN

GB00BP2C3V08

Issuer Name

GENFLOW BIOSCIENCES PLC

UK or Non-UK Issuer

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

MR ERIC LEIRE

City of registered office (if applicable)

15 Ingestre Place,

Country of registered office (if applicable)

Name	City of registered office	Country of registered office
Eric Leire

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

27-Mar-2025

6. Date on which Issuer notified

27-Mar-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	36.180000	0.000000	36.180000	126514999
Position of previous notification (if applicable)	35.600000	0.000000	35.600000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BP2C3V08	126514999	36.180000
Sub Total 8.A	126514999		36.180000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

12. Date of Completion

27-Mar-2025

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com .

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

Y.Baker--AT

Arizona Tribune - Genflow Biosciences PLC Announces Holding in Company

Genflow Biosciences PLC Announces Holding in Company

Featured

InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 03

Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

US jury deadlocks again in Lindsay Clancy's child murder trial

Maltese tycoon acquitted of masterminding reporter's murder